GlassScriptPhysician profile
Mohammad A Abu-Rub
NPI 1154689255
$1,321.09
in general payments reported to CMS, 2019-2025
16 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2021: $61.02 · 2022: $702 · 2023: $209 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $343.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $340.64 | 2022-2023 | Uplizna |
| Avanir Pharmaceuticals, INC. | $183.97 | 2022 | |
| Tg Therapeutics, INC. | $154.17 | 2023-2025 | |
| Abbvie INC. | $133.83 | 2022-2023 | Ubrelvy, Qulipta |
| Csl Behring | $121.73 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.39 | 2021-2023 | Gammagard |
| Genentech USA, INC. | $87.49 | 2021-2023 | Ocrevus |
| Alexion Pharmaceuticals, INC. | $57.24 | 2019 | |
| Allergan, INC. | $35.75 | 2019 | |
| Argenx US, INC. | $29.06 | 2022 | |
| Biogen, INC. | $21.59 | 2023 | Vumerity |
| Ucb, INC. | $19.59 | 2021 | |
| Genentech, INC. | $17.17 | 2022 | |
| Eisai INC. | $16.47 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Abu-Rub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.